JOURNEY MEDICAL CORP (DERM)

US48115J1097 - Common Stock

3.91  -0.09 (-2.25%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to DERM. DERM was compared to 192 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of DERM have multiple concerns. DERM has a expensive valuation and it also scores bad on growth.



Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year DERM has reported negative net income.
In the past year DERM has reported a negative cash flow from operations.
The reported net income has been mixed in the past 5 years: DERM reported negative net income in multiple years.
In multiple years DERM reported negative operating cash flow during the last 5 years.

1.2 Ratios

DERM has a Return On Assets (-28.63%) which is in line with its industry peers.
With a Return On Equity value of -167.82%, DERM is not doing good in the industry: 66.30% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -28.63%
ROE -167.82%
ROIC N/A
ROA(3y)-26.13%
ROA(5y)-11.5%
ROE(3y)-99.32%
ROE(5y)-23.41%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

In the last couple of years the Operating Margin of DERM has declined.
DERM has a better Gross Margin (57.32%) than 64.67% of its industry peers.
In the last couple of years the Gross Margin of DERM has declined.
The Profit Margin and Operating Margin are not available for DERM so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 57.32%
OM growth 3Y-57.52%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.45%
GM growth 5Y-7.36%

More info and screens

2

2. Health

2.1 Basic Checks

DERM does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for DERM has been increased compared to 1 year ago.
DERM has less shares outstanding than it did 5 years ago.
The debt/assets ratio for DERM has been reduced compared to a year ago.

2.2 Solvency

Based on the Altman-Z score of -1.05, we must say that DERM is in the distress zone and has some risk of bankruptcy.
DERM has a Altman-Z score (-1.05) which is comparable to the rest of the industry.
A Debt/Equity ratio of 1.81 is on the high side and indicates that DERM has dependencies on debt financing.
Looking at the Debt to Equity ratio, with a value of 1.81, DERM is doing worse than 78.26% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 1.81
Debt/FCF N/A
Altman-Z -1.05
ROIC/WACCN/A
WACC10.18%

2.3 Liquidity

A Current Ratio of 1.38 indicates that DERM should not have too much problems paying its short term obligations.
DERM's Current ratio of 1.38 is on the low side compared to the rest of the industry. DERM is outperformed by 77.72% of its industry peers.
A Quick Ratio of 1.03 indicates that DERM should not have too much problems paying its short term obligations.
DERM's Quick ratio of 1.03 is on the low side compared to the rest of the industry. DERM is outperformed by 78.80% of its industry peers.
Industry RankSector Rank
Current Ratio 1.38
Quick Ratio 1.03

More info and screens

3

3. Growth

3.1 Past

The earnings per share for DERM have decreased strongly by -50.00% in the last year.
Looking at the last year, DERM shows a very negative growth in Revenue. The Revenue has decreased by -27.69% in the last year.
DERM shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 13.34% yearly.
EPS 1Y (TTM)-50%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-121.25%
Revenue 1Y (TTM)-27.69%
Revenue growth 3Y21.15%
Revenue growth 5Y13.34%
Sales Q2Q%-57.64%

3.2 Future

Based on estimates for the next years, DERM will show a quite strong growth in Earnings Per Share. The EPS will grow by 19.74% on average per year.
Based on estimates for the next years, DERM will show a small growth in Revenue. The Revenue will grow by 5.73% on average per year.
EPS Next Y-464.78%
EPS Next 2Y22.07%
EPS Next 3Y19.74%
EPS Next 5YN/A
Revenue Next Year-28.24%
Revenue Next 2Y-1.03%
Revenue Next 3Y5.73%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for DERM. In the last year negative earnings were reported.
Also next year DERM is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

DERM's earnings are expected to grow with 19.74% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y22.07%
EPS Next 3Y19.74%

More info and screens

0

5. Dividend

5.1 Amount

DERM does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

JOURNEY MEDICAL CORP

NASDAQ:DERM (1/10/2025, 10:27:14 AM)

3.91

-0.09 (-2.25%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-12 2024-11-12/amc
Earnings (Next)N/A N/A
Inst Owners16.19%
Inst Owner Change0%
Ins Owners7.99%
Ins Owner Change0.47%
Market Cap58.22M
Analysts82
Price Target10.2 (160.87%)
Short Float %0.65%
Short Ratio0.55
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-14.64%
Min EPS beat(2)-16.28%
Max EPS beat(2)-12.99%
EPS beat(4)0
Avg EPS beat(4)-50.96%
Min EPS beat(4)-121.11%
Max EPS beat(4)-12.99%
EPS beat(8)2
Avg EPS beat(8)45.77%
EPS beat(12)3
Avg EPS beat(12)3.89%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)2.3%
Min Revenue beat(2)-0.31%
Max Revenue beat(2)4.92%
Revenue beat(4)1
Avg Revenue beat(4)-1.37%
Min Revenue beat(4)-9.39%
Max Revenue beat(4)4.92%
Revenue beat(8)3
Avg Revenue beat(8)9.66%
Revenue beat(12)4
Avg Revenue beat(12)3.19%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)9.59%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-127.42%
EPS NY rev (1m)-2.4%
EPS NY rev (3m)-1.7%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-3.21%
Revenue NY rev (1m)0.14%
Revenue NY rev (3m)-0.66%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.01
P/FCF N/A
P/OCF N/A
P/B 5.33
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.99
EYN/A
EPS(NY)-0.09
Fwd EYN/A
FCF(TTM)-1.87
FCFYN/A
OCF(TTM)-1.87
OCFYN/A
SpS3.88
BVpS0.73
TBVpS-0.46
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -28.63%
ROE -167.82%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 57.32%
FCFM N/A
ROA(3y)-26.13%
ROA(5y)-11.5%
ROE(3y)-99.32%
ROE(5y)-23.41%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-57.52%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.45%
GM growth 5Y-7.36%
F-Score1
Asset Turnover0.9
Health
Industry RankSector Rank
Debt/Equity 1.81
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.38
Quick Ratio 1.03
Altman-Z -1.05
F-Score1
WACC10.18%
ROIC/WACCN/A
Cap/Depr(3y)334.96%
Cap/Depr(5y)254.56%
Cap/Sales(3y)16.43%
Cap/Sales(5y)11.77%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-50%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-121.25%
EPS Next Y-464.78%
EPS Next 2Y22.07%
EPS Next 3Y19.74%
EPS Next 5YN/A
Revenue 1Y (TTM)-27.69%
Revenue growth 3Y21.15%
Revenue growth 5Y13.34%
Sales Q2Q%-57.64%
Revenue Next Year-28.24%
Revenue Next 2Y-1.03%
Revenue Next 3Y5.73%
Revenue Next 5YN/A
EBIT growth 1Y-164.15%
EBIT growth 3Y-48.54%
EBIT growth 5YN/A
EBIT Next Year249.67%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y18.29%
FCF growth 3Y-60.62%
FCF growth 5YN/A
OCF growth 1Y-115.89%
OCF growth 3Y0.71%
OCF growth 5YN/A